Opko Health

Opko Health

Yahoo Finance • 3 days ago

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

It has been about a month since the last earnings report for OPKO Health (OPK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release,... Full story

Yahoo Finance • 5 days ago

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health, Inc. OPK is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE's strong performance, strategic partnerships, BioReference restructuri... Full story

Yahoo Finance • 17 days ago

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK)... Full story

Yahoo Finance • 20 days ago

Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28

(RTTNews) - Entera Bio Ltd. (ENTX), a clinical-stage biopharmaceutical company, reported a wider net loss for the second quarter, on surge in financial expense and more than double the growth in research and development expenses. Further,... Full story

Yahoo Finance • 27 days ago

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Cocrystal Pharma, Inc. Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocry... Full story

Yahoo Finance • last month

Biggest stock movers Tuesday: APLD, CLS, and more

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures showed mixed activity Tuesday morning as investors awaited key technology sector earnings that could shape the outlook for artificial in... Full story

Yahoo Finance • last month

OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ...

This article first appeared on GuruFocus. Cash Position: Over $300 million in cash, cash equivalents, and restricted cash. Share Repurchase: 9.7 million shares repurchased for approximately $13 million. Diagnostics Revenue: $74.5 million... Full story

Yahoo Finance • last month

OPKO Health Q2 2026 Earnings Preview

* OPKO Health (OPK [https://seekingalpha.com/symbol/OPK]) is scheduled to announce Q2 earnings results on Monday, July 27th, after market close. * The consensus EPS estimate is -$0.08, [https://seekingalpha.com/symbol/OPK/earnings/esti... Full story

Yahoo Finance • 2 months ago

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class d... Full story

Yahoo Finance • 4 months ago

OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...

This article first appeared on GuruFocus. Revenue: $124.2 million for Q1 2026, down from $149.9 million in Q1 2025. Diagnostics Revenue: $72.2 million in Q1 2026, including $6.5 million from 4K score test. Pharmaceutical Revenue: $52 mill... Full story

Yahoo Finance • 4 months ago

OPKO Health GAAP EPS of -$0.07 in-line, revenue of $124.2M misses by $6.57M

* OPKO Health press release [https://seekingalpha.com/pr/20491381-opko-health-reports-first-quarter-2026-business-highlights-and-financial-results] (OPK [https://seekingalpha.com/symbol/OPK]): Q1 GAAP EPS of -$0.07 in-line. * Revenue o... Full story

Yahoo Finance • 4 months ago

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

OPKO Health, Inc. Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of Hematology (ASH) Annual Meet... Full story

Yahoo Finance • 5 months ago

OPKO Health, Inc. (OPK) Makes Progress on Game changing Covid-19 Treatment

OPKO Health, Inc. (NASDAQ:OPK) is one of the best healthcare penny stocks to buy according to hedge funds. On April 9, H.C. Wainwright reiterated its Buy rating on Opko Health (NASDAQ:OPK) and $3 price target, impressed by the company’s Ph... Full story

Yahoo Finance • 6 months ago

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Date Feb. 26, 2026 Call participants Chairman and Chief Executive Officer — Phillip FrostVice Chairman and President — Elias ZerhouniChief Financial Officer — Adam E. LogalIndependent Director and Chief I... Full story

Yahoo Finance • 7 months ago

Opko Health (OPK) Expands Entera Partnership for Drug Co-Development

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replaceme... Full story

Yahoo Finance • 9 months ago

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Pa... Full story

Yahoo Finance • 10 months ago

NextPlat Reports Third Quarter 2025 Results

Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026 HALLANDALE BEACH, Fla., Nov. 13, 2025 /PRNewswir... Full story

Yahoo Finance • 10 months ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and rece... Full story

Yahoo Finance • 10 months ago

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

OPKO Health, Inc. First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28, 20... Full story

Yahoo Finance • 10 months ago

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, O... Full story